

23 July 2026

Oncology Treatments

1. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

All NSCLC – stage not available in time given

- Atezolizumab (Tecentriq) <5
- Durvalumab (Imfinzi) <5
- Nivolumab (Opdivo) 0
- Pembrolizumab (Keytruda) 11
- Chemotherapy Alectinib <5, Cis/Vinor 8, Crizotinib <5, GemCarbo <5, NintDoc <5, NivoPacCarbo <5, OsiPemCarbo <5, PacCarbo <5, PemCarbo 5, PembGemCarb <5, PembPemCarb 6, PembroSCPemCarbMet <5, Selpercatinib <5, Sotorasib <5.

- Radiotherapy

Within the Radiotherapy Aria system, we do not categorise NSCLC or Disease stage.

From referral data we received 37 Radical NSCLC referrals within the last 3 months.

- Chemotherapy AND Radiotherapy CarboVinXRT 7, PacCarboXRT <5
- Osimertinib 8

* Where numbers are low we have put <5 rather than state the actual figure. To ensure that patient remain non identifiable. Disclosure of this information would breach the first data protection principle, which relates to the fair and lawful processing of personal data. Therefore, we have concluded that this information is exempt from disclosure under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party.